- Home
- HSBC vs NVO Comparison
HSBC vs NVO Comparison
Compare HSBC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | NVO |
|---|---|---|
| Founded | 1865 | 1923 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.5B | 212.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HSBC | NVO |
|---|---|---|
| Price | $74.89 | $48.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | N/A | ★ $54.25 |
| AVG Volume (30 Days) | 1.7M | ★ 18.5M |
| Earning Date | 10-28-2025 | 02-04-2026 |
| Dividend Yield | ★ 4.37% | 2.45% |
| EPS Growth | N/A | ★ 10.06 |
| EPS | 0.93 | ★ 3.67 |
| Revenue | ★ $57,976,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $12.50 | $7.77 |
| Revenue Next Year | $2.06 | $1.86 |
| P/E Ratio | $80.68 | ★ $13.69 |
| Revenue Growth | 0.01 | ★ 16.64 |
| 52 Week Low | $45.66 | $43.08 |
| 52 Week High | $75.44 | $111.17 |
Technical Indicators
Market Signals| Indicator | HSBC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 66.35 | 49.52 |
| Support Level | $74.37 | $46.08 |
| Resistance Level | $75.92 | $50.75 |
| Average True Range (ATR) | 0.68 | 1.09 |
| MACD | 0.41 | 0.45 |
| Stochastic Oscillator | 83.05 | 60.49 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.